Teva Deal for Allergan Generics Unit Expected to Get Europe OK -Reuters
09 Mars 2016 - 9:54PM
Dow Jones News
European antitrust regulators are expected to approve Teva
Pharmaceutical Industries Ltd.'s (TEVA) purchase of Allergan PLC's
(AGN) generic drugs business, Reuters reported Wednesday.
The cash-and-stock deal was worth $40.5 billion when it was
announced in July.
According to the report, Teva will divest some products to
address competition concerns.
Full story at:
http://www.reuters.com/article/us-allergan-m-a-teva-pharm-ind-eu-idUSKCN0WB2LT
Write to nymonitoring@dowjones.com
(END) Dow Jones Newswires
March 09, 2016 15:39 ET (20:39 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
